Tchelebi Leila, Zaorsky Nicholas, Mackley Heath
Penn State Health Milton S. Hershey Medical Center, Hershey, PA 17033, USA.
Biomedicines. 2018 Jan 3;6(1):7. doi: 10.3390/biomedicines6010007.
The role of external beam radiation therapy (EBRT) in the management of upper gastrointestinal malignancies is constantly evolving. As radiation therapy techniques improve and are able to deliver more ablative doses of radiotherapy while sparing healthy tissue, radiation can be applied to a wider range of clinical scenarios. Stereotactic body radiation therapy (SBRT) allows a high dose of radiation to be delivered to a highly conformal treatment volume in a short amount of time. Another potential advantage of SBRT is its ability to increase tumor immunogenicity, while also having less of an immunosuppressive effect on the patient, as compared to conventionally fractionated radiation therapy. In so doing, SBRT may potentiate the effects of immune therapy when the two treatments are combined, thus improving therapeutic outcomes. This article provides an overview of the role of SBRT in the management of upper gastrointestinal GI malignancies and the emerging data on immune biomarkers and SBRT, with a focus on pancreatic and liver cancer.
外照射放射治疗(EBRT)在上消化道恶性肿瘤治疗中的作用不断演变。随着放射治疗技术的进步,能够在保护健康组织的同时给予更高的消融放疗剂量,放射治疗可应用于更广泛的临床场景。立体定向体部放射治疗(SBRT)能在短时间内将高剂量放射治疗精准投送至高度适形的治疗靶区。与传统分割放疗相比,SBRT的另一个潜在优势是其能够增强肿瘤免疫原性,同时对患者的免疫抑制作用较小。如此一来,当这两种治疗方法联合使用时,SBRT可能会增强免疫治疗的效果,从而改善治疗结果。本文概述了SBRT在上消化道恶性肿瘤治疗中的作用以及关于免疫生物标志物和SBRT的最新数据,重点关注胰腺癌和肝癌。